Biotheryx
San Diego, US · 1 known investors
Biotheryx discovers and develops targeted protein degrader drugs designed to treat cancer and inflammatory diseases. The company uses its proprietary PRODEGY platform to create molecular glues and bifunctional degraders, with lead programs in clinical trials for oncology indications including breast cancer and hematologic malignancies.
BiotechMedical Devices